Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

BACKGROUND: Type 2 diabetes mellitus is a progressive metabolic disease necessitating therapies with sustained efficacy and safety over time. Exenatide once weekly (ExQW), an extended-release formulation of the glucagon-like peptide-1 receptor agonist exenatide, has demonstrated improvements in glyc...

Full description

Saved in:
Bibliographic Details
Main Authors: MacConell, Leigh, Pencek, Richard, Li, Yan, Maggs, David, Porter, Lisa
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2013
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3555554/
https://ncbi.nlm.nih.gov/pubmed/23358123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S35801
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items